NEW YORK, Oct. 28, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=109394&from=4 CLASS PERIOD: This lawsuit is on beha ...

Core Insights - Metagenomi's Adenine Base Editors (ABEs) demonstrate over 95% genome targetability and achieve over 95% protein knockdown in primary T-cells, indicating high efficiency and specificity in gene editing applications [1][2][3] Group 1: Targetability - The ABE platform is targetable to over 95% of the human genome's base pairs, providing a significantly wider range of sites compared to first-generation SpCas9 base editors, which enhances flexibility in addressing complex gene targets [2][3] Group 2: Efficiency - The ABE platform achieved over 95% reproducible and durable triplex protein knockdown in primary T-cells, confirming its efficiency for multiplex gene editing [3] - The platform is compatible with various non-viral methods for site-specific template integration, enabling a comprehensive editing solution for next-generation cell therapies [3] Group 3: Specificity - The ABE demonstrated highly specific on-target deamination with minimal to no indel formation, confirming no detectable translocations and no significant genomic composition differences compared to unedited cells, which minimizes the risk of unintended genetic alterations [3] Group 4: Tolerability - ABE triplex protein knockdowns exhibited excellent tolerability in cells, with no adverse effects on cell viability, expansion, or changes in stress-related gene expression observed post-editing, which is critical for maintaining cell health in therapeutic applications [4] Group 5: Company Overview - Metagenomi is a precision genetic medicines company focused on developing curative therapeutics using its proprietary metagenomics-derived toolbox, which includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems [5]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Metagenomi, Inc. regarding a class action lawsuit related to the company's initial public offering and subsequent termination of its collaboration with Moderna, which has impacted the stock price significantly [1][3]. Summary by Sections Class Action Details - The lawsuit is on behalf of shareholders who purchased Metagenomi stock during the class period from February 9 to 13, 2024, coinciding with the company's IPO [2]. - Shareholders are encouraged to register for participation in the class action, with a deadline set for November 25, 2024 [4]. Allegations and Impact - Metagenomi presented itself as a "genetic medicines company" with a strategic partnership with Moderna, which was a key aspect of its business model [3]. - The company completed its IPO on February 13, 2024, selling 6.25 million shares at $15 each, but announced the termination of its collaboration with Moderna on May 1, 2024 [3]. - Following the announcement, Metagenomi's stock price fell from $7.04 on May 1, 2024, to $6.17 on May 2, 2024, indicating a significant market reaction to the news [3]. Next Steps for Shareholders - Shareholders who register will receive updates through a portfolio monitoring software regarding the case's progress [4]. - There is no cost or obligation for shareholders to participate in the class action [4]. Law Firm Background - The Gross Law Firm is recognized for its commitment to protecting investors' rights and addressing issues of deceit and fraud in business practices [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Metagenomi, Inc. due to alleged violations of federal securities laws related to misleading statements about its collaboration with Moderna, which has led to significant investor losses [1][2]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Metagenomi between February 9, 2024, and September 26, 2024, to discuss their legal options [1]. - A federal securities class action has been filed against Metagenomi, with a deadline of November 25, 2024, for investors to seek the role of lead plaintiff [1][4]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [1]. Group 2: Allegations Against Metagenomi - The complaint alleges that Metagenomi and its executives made false and misleading statements regarding their collaboration with Moderna, which was a key aspect of their business model [2]. - Metagenomi's initial public offering took place on February 13, 2024, selling 6.25 million shares at $15 per share [3]. - The collaboration with Moderna was terminated on May 1, 2024, leading to a significant drop in Metagenomi's stock price from $7.04 to $6.17 per share within a day [3]. Group 3: Investor Participation and Information - The lead plaintiff in the class action is defined as the investor with the largest financial interest who is typical of class members [4]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [4]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Metagenomi's conduct [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Company Overview - Metagenomi, Inc. is described as a "genetic medicines company" that had a collaboration with Moderna, a leading Covid-19 vaccine company [3] - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [3] Group 2: Legal Proceedings - A class action lawsuit has been filed against Metagenomi following the announcement on May 1, 2024, that the collaboration agreement with Moderna was mutually terminated [3] - Investors are encouraged to join the class action, with a lead plaintiff deadline set for November 25, 2024 [1][4] Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [2] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [2]

Core Viewpoint - A securities class action lawsuit has been filed against Metagenomi Inc. for allegedly misleading investors regarding its prospects and relationship with Moderna during the class period from February 6, 2024, to September 26, 2024 [1][3]. Company Overview - Metagenomi Inc. is described as a "genetic medicines company" based in Emeryville, CA, with a significant partnership with Moderna, a leading Covid-19 vaccine company [2]. - The collaboration with Moderna included a Strategic Collaboration and License Agreement established on October 29, 2021, which involved multiple four-year research programs and subsequent licensed product agreements [2]. Key Events - On May 1, 2024, Metagenomi announced the mutual termination of its collaboration agreement with Moderna, which analysts noted was critical to Metagenomi's business model [3]. - Following the announcement, Metagenomi's share price dropped from $7.04 per share to $6.17 per share within a day, continuing to decline to slightly above $2.00 per share at the time of the lawsuit filing [3]. Legal Proceedings - Investors who purchased Metagenomi securities during the class period can seek to be appointed as lead plaintiff representatives by November 25, 2024 [2][4]. - The lawsuit claims that Metagenomi and its senior executives misled investors about the company's future prospects and its relationship with Moderna [3].

Lawsuit Overview - A class action lawsuit has been filed against Metagenomi Inc on behalf of investors who acquired its securities between February 9 2024 and May 1 2024 [1] - Investors have until November 25 2024 to apply to be appointed as lead plaintiff in the lawsuit [1] IPO and Stock Performance - Metagenomi conducted its IPO on February 12 2024 selling approximately 6 25 million shares at $15 per share [1] - On May 1 2024 Metagenomi announced the termination of its collaboration with Moderna leading to a 12 4% decline in share price from $7 04 to $6 17 [1] Allegations in the Lawsuit - The lawsuit alleges that Metagenomi's IPO registration statements were false and/or materially misleading [2] - Metagenomi represented itself as having a long-standing business relationship with Moderna but the collaboration was terminated shortly after the IPO [2] Law Firm Information - Kirby McInerney LLP is handling the lawsuit and has a history of recovering billions of dollars for shareholders in securities litigation [3]

Core Viewpoint - Metagenomi, Inc. is facing a class action lawsuit following the termination of its collaboration with Moderna, which was a significant aspect of its initial public offering narrative [2]. Group 1: Company Overview - Metagenomi, Inc. is characterized as a "genetic medicines company" with a prior collaboration with Moderna, a leading Covid-19 vaccine company [2]. - The company completed its initial public offering on February 13, 2024, selling 6.25 million shares at a price of $15 per share [2]. Group 2: Legal Allegations - The lawsuit alleges that Metagenomi misled investors regarding its partnership with Moderna, which was crucial to its business model [2]. - The collaboration agreement with Moderna, established on October 29, 2021, included multiple four-year research programs [2]. - Following the announcement of the termination of the collaboration on May 1, 2024, Metagenomi's stock price fell from $7.04 to $6.17 per share within a day [2]. Group 3: Shareholder Actions - Shareholders who purchased shares during the specified class period are encouraged to register for the class action lawsuit, with a deadline of November 25, 2024, to seek lead plaintiff status [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3].

SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who purchased stock pursuant to and/or traceable to Metagenomi Inc.'s (NASDAQ: MGX) registration statement for the initial public offering (IPO) held between February 9 and 13, 2024. Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. For more information, ...

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=108485&from=3 CLASS PERIOD: This lawsuit is on ...